aripiprazole has been researched along with Basal Ganglia Diseases in 52 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 34 (65.38) | 29.6817 |
| 2010's | 18 (34.62) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Coolen, HK; Glennon, JC; Kruse, CG; Lange, JH; Reinders, JH; Tolboom, JT | 1 |
| Hammer, T; Ho, J; Patten, S; Pringsheim, T; Sarna, JR | 1 |
| Das, S; Srikanta, MM; Thirthalli, J | 1 |
| Aguiar, PM; de Mendonça Lima, T; Ribeiro, ELA; Storpirtis, S; Vieira, MEB | 1 |
| Arie, C; Fujii, A; Harada, N; Matsuo, K; Obara, K; Tanaka, Y; Yamaki, F; Yoshio, T | 1 |
| Lawlor, BA; Sweeney, EB | 1 |
| Brooks, KR; Kram, BL; Kram, SJ | 1 |
| Fabbri, C; Kato, M; Kinoshita, T; Koshikawa, Y; Nonen, S; Okugawa, G; Sakai, S; Serretti, A; Sunada, N; Takekita, Y; Wakeno, M | 1 |
| Chiu, HF; Li, XB; Lok, GK; Ng, CH; Ungvari, GS; Xiang, YQ; Xiang, YT; Zheng, W; Zhong, BL | 1 |
| Baglivo, V; Balestrieri, M; Brambilla, P; Gregoraci, G; Isola, M; Meduri, M | 1 |
| Bernagie, C; Danckaerts, M; De Hert, M; Wampers, M | 1 |
| Cocker, KE; Reese, TR; Thiel, DJ | 1 |
| Carleton, BC; Etminan, M; Procyshyn, RM; Samii, A | 1 |
| Alphs, L; Correll, CU; Kim, E; Mao, L; Starr, HL | 1 |
| Carson, WH; Findling, RL; Forbes, RA; Ivanova, S; Iwamoto, T; Jin, N; Marcus, R; McQuade, RD; Nyilas, M; Robb, A | 1 |
| Kusnir, D; LoPiccolo, M; Sandoz, A; Tausk, FA | 1 |
| Kashima, H; Kikuchi, T; Manki, H; Nakajima, S; Nomura, K; Suzuki, T; Takeuchi, H; Uchida, H; Watanabe, K | 1 |
| Cho, SJ; Jang, JH; Kang, DH; Kim, YK; Kwon, JS; Yoo, SY | 1 |
| Deng, C; Han, M; Huang, XF | 1 |
| Assunção-Talbott, S; Eudicone, JM; Glick, ID; Mankoski, R; Marcus, RN; Tran, QV | 1 |
| Christodoulou, C; Douzenis, A; Gournellis, R; Lykouras, LP; Rizos, E | 1 |
| Baker, RA; Docherty, JP; Eudicone, J; Mankoski, R; Marcus, RN; Mathew, S; McQuade, RD | 1 |
| Gründer, G; Gur, R; Hiemke, C; Schiffl, K; Schorn, H; Vernaleken, I; Veselinović, T; Zernig, G | 1 |
| Carson, WH; Findling, RL; Kamen, L; Mankoski, R; Manos, G; Marcus, RN; McQuade, RD; Owen, R | 1 |
| Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T | 1 |
| Calì, PV; Gulisano, M; Rizzo, R | 1 |
| Ali, MW; Carson, WH; Ingenito, GG; Kane, JM; McQuade, RD; Saha, AR; Zimbroff, DL | 1 |
| Ali, M; Carson, WH; Ingenito, G; Kujawa, MJ; Marder, SR; Potkin, SG; Saha, AR; Stock, E; Stringfellow, J | 1 |
| Ali, M; Ingenito, G; Keck, PE; Liebeskind, A; Marcus, R; Saha, A; Tourkodimitris, S | 1 |
| Carlsson, A; Grunder, G; Wong, DF | 1 |
| Kaplan, D; Koliatsos, V; Lindsey, RL; Sandson, NB; Walters, JK | 1 |
| Mendhekar, DN | 1 |
| Ismail, MS; Profenno, LA; Tariot, PN | 1 |
| Baum, CR; Douglas, L; Schonberger, RB | 1 |
| Cohen, ST; Pies, R; Rulf, D | 1 |
| Keck, PE | 1 |
| Dubois, D | 1 |
| Hatchett, AD; Zacher, JL | 1 |
| Odiyoor, M; Salmoiraghi, A | 1 |
| Calliess, IT; Kropp, S; Sieberer, M; Ziegenbein, M | 1 |
| Andrezina, R; Carson, WH; Iwamoto, T; Josiassen, RC; Manos, G; Marcus, RN; Oren, DA; Stock, E | 1 |
| Carson, WH; Kane, JM; Marcus, RN; McQuade, RD; Meltzer, HY; Sanchez, R | 1 |
| Limosin, F | 1 |
| Brahm, NC; Brown, RC; McElwain, DL | 1 |
| Carson, WH; Daniel, DG; Marcus, RN; McEvoy, JP; McQuade, RD | 1 |
| Carson, WH; Crandall, DT; Eudicone, J; Kane, JM; Marcus, RN; Pikalov, A; Swyzen, W | 1 |
| Graff, A; Kapur, S; Mamo, D; Mizrahi, R; Romeyer, F; Shammi, CM | 1 |
| Chen, YY; Hung, GC | 1 |
| Blow, FC; Cassidy, KA; Coconcea, N; Hays, RW; Ignacio, RV; Meyer, WJ; Sajatovic, M | 1 |
| Hazra, M; Mamo, DC; Remington, G | 1 |
| Poyurovsky, M; Weizman, A; Weizman, R | 1 |
| Stahl, SM | 1 |
12 review(s) available for aripiprazole and Basal Ganglia Diseases
| Article | Year |
|---|---|
Efficacy and safety of aripiprazole for the treatment of schizophrenia: an overview of systematic reviews.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Cholesterol; Glucose Metabolism Disorders; Humans; Lipid Metabolism; Schizophrenia; Treatment Outcome; Weight Gain | 2018 |
Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Child; Haloperidol; Humans; Randomized Controlled Trials as Topic; Severity of Illness Index; Tourette Syndrome; Treatment Outcome | 2016 |
A meta-analysis of efficacy and safety of aripiprazole in adult and pediatric bipolar disorder in randomized controlled trials and observational studies.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Child; Gastrointestinal Diseases; Humans; Hyperprolactinemia; Male; Middle Aged; Observational Studies as Topic; Randomized Controlled Trials as Topic; Treatment Outcome; Weight Gain; Young Adult | 2016 |
Aripiprazole and Acute Extrapyramidal Symptoms in Children and Adolescents: A Meta-Analysis.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Child; Dyskinesia, Drug-Induced; Humans; Incidence | 2016 |
Behavioral Disorders in Dementia: Appropriate Nondrug Interventions and Antipsychotic Use.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Behavior Therapy; Benzodiazepines; Cognitive Behavioral Therapy; Dementia; Emotions; Humans; Hypotension, Orthostatic; Metabolic Syndrome; Neuroleptic Malignant Syndrome; Olanzapine; Practice Guidelines as Topic; Psychotic Disorders; Quetiapine Fumarate; Risperidone | 2016 |
A clinical paradigm of delusions of parasitosis.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Diagnosis, Differential; Female; Humans; Metabolic Syndrome; Middle Aged; Olanzapine; Pain; Patient Compliance; Peripheral Nervous System Diseases; Piperazines; Quinolones; Schizophrenia, Paranoid; Skin Diseases, Parasitic; Sleep Wake Disorders | 2008 |
Mechanism of new antipsychotic medications: occupancy is not just antagonism.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Corpus Striatum; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Prolactin; Putamen; Quinolones; Receptors, Dopamine D2; Schizophrenia; Tomography, Emission-Computed | 2003 |
Efficacy of atypical antipsychotics in elderly patients with dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Treatment Outcome | 2004 |
The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania.
Topics: Acute Disease; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Bipolar Disorder; Clozapine; Dibenzothiazepines; Double-Blind Method; Humans; Lithium; Olanzapine; Piperazines; Placebos; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone; Treatment Outcome | 2005 |
Toxicology and overdose of atypical antipsychotic medications in children: does newer necessarily mean safer?
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Cardiomyopathies; Child; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Drug Interactions; Drug Overdose; Dry Eye Syndromes; Humans; Hyperlipidemias; Hypotension; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Seizures; Thiazoles | 2005 |
[The use of atypical antipsychotics in the long-term care of schizophrenia].
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Cognition Disorders; Drug Tolerance; Dyskinesia, Drug-Induced; Haloperidol; Humans; Olanzapine; Piperazines; Quinolones; Risperidone; Schizophrenia; Sulpiride; Time Factors | 2006 |
Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks.
Topics: Acute Disease; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Haloperidol; Humans; Longitudinal Studies; Piperazines; Prospective Studies; Psychiatric Status Rating Scales; Quinolones; Randomized Controlled Trials as Topic; Research Design; Schizophrenia; Schizophrenic Psychology; Survival Analysis; Treatment Outcome | 2007 |
16 trial(s) available for aripiprazole and Basal Ganglia Diseases
| Article | Year |
|---|---|
Antagonist and partial agonist at the dopamine D2 receptors in drug-naïve and non-drug-naïve schizophrenia: a randomized, controlled trial.
Topics: Adult; Aged; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine D2 Receptor Antagonists; Drug Partial Agonism; Female; Humans; Isoindoles; Male; Middle Aged; Receptors, Dopamine D2; Schizophrenia; Schizophrenic Psychology; Thiazoles; Treatment Outcome; Young Adult | 2015 |
Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Delayed-Action Preparations; Female; Haloperidol; Humans; Hyperprolactinemia; Injections, Intramuscular; Male; Middle Aged; Olanzapine; Paliperidone Palmitate; Perphenazine; Proportional Hazards Models; Quetiapine Fumarate; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Failure; Treatment Outcome | 2016 |
A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Diagnostic and Statistical Manual of Mental Disorders; Dose-Response Relationship, Drug; Double-Blind Method; Female; Humans; Male; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2008 |
A randomized, open-label comparison of 2 switching strategies to aripiprazole treatment in patients with schizophrenia: add-on, wait, and tapering of previous antipsychotics versus add-on and simultaneous tapering.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Schizophrenic Psychology; Severity of Illness Index | 2008 |
Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Diagnostic and Statistical Manual of Mental Disorders; Double-Blind Method; Female; Haloperidol; Humans; Male; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Quinolones; Schizophrenia; Schizophrenic Psychology; Sleep Initiation and Maintenance Disorders; Social Behavior Disorders; Young Adult | 2010 |
Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine; Female; Haloperidol; Humans; Male; Piperazines; Psychiatric Status Rating Scales; Quinolones; Reserpine; Single-Blind Method; Young Adult | 2011 |
Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: a 52-week, open-label, multicenter study.
Topics: Adolescent; Aggression; Alanine Transaminase; Antipsychotic Agents; Aripiprazole; Aspartate Aminotransferases; Autistic Disorder; Basal Ganglia Diseases; Child; Drug Tolerance; Female; Humans; Irritable Mood; Male; Piperazines; Quinolones; Weight Gain | 2011 |
Effects of paroxetine on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients with schizophrenia.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Asian People; Basal Ganglia Diseases; Chromatography, Liquid; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Japan; Male; Mass Spectrometry; Middle Aged; Paroxetine; Piperazines; Psychiatric Status Rating Scales; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors; Severity of Illness Index; Young Adult | 2012 |
Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Double-Blind Method; Drug Administration Schedule; Electroencephalography; Female; Haloperidol; Humans; Hyperprolactinemia; Long QT Syndrome; Male; Piperazines; Placebos; Prolactin; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Secondary Prevention; Treatment Outcome | 2002 |
Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Female; Hospitalization; Humans; Male; Piperazines; Placebos; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Risperidone; Schizophrenia; Schizophrenic Psychology; Treatment Outcome | 2003 |
A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Double-Blind Method; Female; Humans; Male; Piperazines; Placebos; Quinolones; Treatment Outcome | 2003 |
Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Anti-Dyskinesia Agents; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Blood Glucose; Double-Blind Method; Drug Therapy, Combination; Female; Haloperidol; Humans; Injections, Intramuscular; Male; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quinolones; Schizophrenia; Time Factors; Treatment Outcome; Withholding Treatment | 2006 |
Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Double-Blind Method; Drug Resistance; Female; Humans; Male; Perphenazine; Piperazines; Prolactin; Quality of Life; Quinolones; Severity of Illness Index; Treatment Outcome | 2007 |
A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia.
Topics: Acute Disease; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Weight; Dose-Response Relationship, Drug; Double-Blind Method; Electrocardiography; Female; Humans; Male; Middle Aged; Piperazines; Prolactin; Psychiatric Status Rating Scales; Quinolones; Schizophrenia | 2007 |
Differential effects of aripiprazole on D(2), 5-HT(2), and 5-HT(1A) receptor occupancy in patients with schizophrenia: a triple tracer PET study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia; Basal Ganglia Diseases; Carbon Radioisotopes; Caudate Nucleus; Cerebral Cortex; Dopamine D2 Receptor Antagonists; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorine Radioisotopes; Humans; Male; Piperazines; Positron-Emission Tomography; Psychotic Disorders; Putamen; Pyridines; Pyrimidinones; Quinolones; Raclopride; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Treatment Outcome | 2007 |
Aripiprazole therapy in 20 older adults with bipolar disorder: a 12-week, open-label trial.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Depressive Disorder; Drug Synergism; Drug Therapy, Combination; Electrocardiography; Female; Humans; Interview, Psychological; Lamotrigine; Lithium Carbonate; Male; Middle Aged; Pilot Projects; Piperazines; Prospective Studies; Quinolones; Triazines; Valproic Acid | 2008 |
24 other study(ies) available for aripiprazole and Basal Ganglia Diseases
| Article | Year |
|---|---|
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolactinemia; Indoles; Metabolic Diseases; Phthalimides; Piperazines; Principal Component Analysis; Pyridines; Radioligand Assay; Receptors, Biogenic Amine; Weight Gain | 2007 |
Feasibility and Relevance of Antipsychotic Safety Monitoring in Children With Tourette Syndrome: A Prospective Longitudinal Study.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Child; Drug Monitoring; Feasibility Studies; Female; Humans; Insulin; Longitudinal Studies; Male; Prolactin; Prospective Studies; Risperidone; Tourette Syndrome; Waist Circumference; Withholding Treatment | 2017 |
Severe extrapyramidal syndrome presenting as catatonia: A rare case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Catatonia; Female; Humans; Syndrome | 2018 |
Inhibition of Recombinant Human Acetylcholinesterase Activity by Antipsychotics.
Topics: Acetylcholinesterase; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Enzyme Assays; GPI-Linked Proteins; HEK293 Cells; Humans; Inhibitory Concentration 50; Recombinant Proteins; Schizophrenia | 2019 |
Case series: extrapyramidal symptoms associated with use of aripiprazole in older adults.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Male; Piperazines; Quinolones; Risk Factors | 2013 |
Implications of atypical antipsychotic prescribing in the intensive care unit.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Basal Ganglia Diseases; Benzodiazepines; Cohort Studies; Delirium; Disorders of Excessive Somnolence; Female; Humans; Inappropriate Prescribing; Intensive Care Units; Male; Middle Aged; Olanzapine; Patient Discharge; Piperazines; Quetiapine Fumarate; Retrospective Studies; Risperidone; Survivors; Thiazoles | 2015 |
Risk of Extrapyramidal Adverse Events With Aripiprazole.
Topics: Administrative Claims, Healthcare; Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Case-Control Studies; Databases, Factual; Drug Prescriptions; Dyskinesia, Drug-Induced; Female; Humans; Male; Middle Aged; Risk; United States; Young Adult | 2016 |
Long-term efficacy and safety of aripiprazole in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder: 26-week prospective study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Body Mass Index; Body Weight; Female; Humans; Korea; Male; Middle Aged; Piperazines; Prolactin; Prospective Studies; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenic Psychology; Suicide; Young Adult | 2009 |
Aripiprazole differentially affects mesolimbic and nigrostriatal dopaminergic transmission: implications for long-term drug efficacy and low extrapyramidal side-effects.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brain; Caudate Nucleus; Dopamine; Dopamine Plasma Membrane Transport Proteins; Gene Expression Regulation, Enzymologic; Haloperidol; Limbic System; Nucleus Accumbens; Olanzapine; Piperazines; Putamen; Quinolones; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; RNA, Messenger; Substantia Nigra; Time Factors; Tyrosine 3-Monooxygenase; Up-Regulation; Ventral Tegmental Area | 2009 |
The efficacy, safety, and tolerability of aripiprazole for the treatment of schizoaffective disorder: results from a pooled analysis of a sub-population of subjects from two randomized, double-blind, placebo-controlled, pivotal trials.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol; Humans; Male; Meta-Analysis as Topic; Middle Aged; Multicenter Studies as Topic; Piperazines; Psychiatric Status Rating Scales; Psychotic Disorders; Quinolones; Randomized Controlled Trials as Topic; Treatment Outcome | 2009 |
Tardive dyskinesia in a patient treated with quetiapine.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dibenzothiazepines; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Piperazines; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Sulpiride; Thiazoles | 2009 |
Oculogyric crisis: a rare extrapyramidal side effect in the treatment of Tourette syndrome.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Eye Movements; Female; Humans; Piperazines; Quinolones; Tourette Syndrome; Young Adult | 2012 |
Aripiprazole and extrapyramidal symptoms.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Piperazines; Quinolones; Schizophrenia | 2003 |
Aripiprazole-induced rabbit syndrome.
Topics: Adult; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Female; Humans; Piperazines; Quinolones; Syndrome | 2004 |
Severe extrapyramidal symptoms in a 3-year-old boy after accidental ingestion of the new antipsychotic drug aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Child, Preschool; Humans; Male; Piperazines; Quinolones | 2004 |
Extrapyramidal side effects associated with aripiprazole coprescription in 2 patients.
Topics: Adult; Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Drug Interactions; Drug Therapy, Combination; Female; Humans; Male; Piperazines; Quinolones; Selective Serotonin Reuptake Inhibitors; Sertraline | 2005 |
Aripiprazole-induced movement disorder.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Bipolar Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Humans; Piperazines; Quinolones; Syndrome | 2006 |
A case of Aripiprazole and extra pyramidal side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Female; Humans; Middle Aged; Piperazines; Quinolones; Schizophrenia | 2006 |
Aripiprazole-induced extrapyramidal side effects in a patient with schizoaffective disorder.
Topics: Adult; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Female; Humans; Piperazines; Psychotic Disorders; Quinolones | 2006 |
Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Topics: Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Baclofen; Basal Ganglia Diseases; Citalopram; Diphenhydramine; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Hypnotics and Sedatives; Male; Mental Disorders; Oxazepam; Piperazines; Quinolones | 2007 |
Combined low-dose clozapine with low-dose aripiprazole in a schizophrenic patient.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Clozapine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Guidelines as Topic; Humans; Male; Piperazines; Quinolones; Risk Assessment; Risperidone; Schizophrenia | 2009 |
Adjunctive versus monotherapeutic treatment for schizophrenia: addressing antipsychotic side effects.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dose-Response Relationship, Drug; Drug Costs; Drug Therapy, Combination; Haloperidol; Humans; Hyperprolactinemia; Piperazines; Polypharmacy; Quinolones; Schizophrenia | 2008 |
Aripiprazole's receptor pharmacology and extrapyramidal side effects.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Humans; Piperazines; Piperidines; Positron-Emission Tomography; Psychomotor Agitation; Quinolones; Receptor, Serotonin, 5-HT1A; Receptors, Dopamine D2; Schizophrenia; Serotonin 5-HT1 Receptor Agonists; Urea | 2008 |
Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action.
Topics: Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Humans; Piperazines; Quinolones; Receptors, Dopamine D2; Schizophrenia; Treatment Outcome | 2001 |